Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. CRC Adjuvant Breast Trial Working Party.

Literature DB >> 2900646

Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. CRC Adjuvant Breast Trial Working Party.

Abstract

In 1980 the Cancer Research Campaign launched a multi-centre breast cancer trial; aimed at repeating the Scandinavian Chemotherapy Study Group's cyclophosphamide trial, and the NATO tamoxifen study; thereby further evaluating the role of these two adjuvant regimens in patients with early breast cancer. Two thousand two hundred and thirty women were randomized into this trial between 1980 and 1985 and preliminary analyses demonstrate a significant improvement in event-free survival for both regimens. Results from this study closely parallel the two trials it set out to repeat.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1988 PMID： 2900646 PMCID： PMC2246453 DOI： 10.1038/bjc.1988.137

Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640

6 in total

1. Six-year results of a controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer.

Authors: A J Wilson; M Baum; D M Brinkley; J A Dossett; K McPherson; J S Patterson; R D Rubens; F G Smiddy; B A Stoll; D Richards
Journal: World J Surg Date: 1985-10 Impact factor: 3.352

2. Adjuvant chemotherapy in breast cancer.

Authors: R Nissen-Meyer; K Kjellgren; B Mansson
Journal: Recent Results Cancer Res Date: 1982

3. Surgical adjuvant chemotherapy: results with one short course with cyclophosphamide after mastectomy for breast cancer.

Authors: R Nissen-Meyer; K Kjellgren; K Malmio; B Månsson; T Norin
Journal: Cancer Date: 1978-06 Impact factor: 6.860

4. Randomised comparative studies in the treatment of cancer in the United Kingdom: room for improvement?

Authors: H C Tate; J B Rawlinson; L S Freedman
Journal: Lancet Date: 1979-09-22 Impact factor: 79.321

5. Antiestrogen treatment of postmenopausal women with primary high risk breast cancer.

Authors: C Rose; S M Thorpe; H T Mouridsen; J A Andersen; H Brincker; K W Andersen
Journal: Breast Cancer Res Treat Date: 1983 Impact factor: 4.872

6. Adjuvant tamoxifen for operable carcinoma of the breast: report of clinical trial by the Christie Hospital and Holt Radium Institute.

Authors: G Ribeiro; M K Palmer
Journal: Br Med J (Clin Res Ed) Date: 1983-03-12

6 in total

19 in total

Review 1. Long-term adjuvant tamoxifen therapy for breast cancer.

Authors: V C Jordan
Journal: Breast Cancer Res Treat Date: 1990-05 Impact factor: 4.872

Review 2. Systemic adjuvant therapy for node-negative breast cancer.

Authors: A D Ginsburg; D J Perrault; K I Pritchard; G P Browman; P B McCulloch; J Skillings
Journal: CMAJ Date: 1989-09-01 Impact factor: 8.262

Review 3. Adjuvant systemic therapy: state of the art, 1989.

Authors: I C Henderson
Journal: Breast Cancer Res Treat Date: 1989-10 Impact factor: 4.872

Review 4. Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program.

Authors: Lori M Minasian; Catherine M Tangen; D Lawrence Wickerham
Journal: Semin Oncol Date: 2015-07-10 Impact factor: 4.929

Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. CRC Adjuvant Breast Trial Working Party.

1. Six-year results of a controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer.

2. Adjuvant chemotherapy in breast cancer.

3. Surgical adjuvant chemotherapy: results with one short course with cyclophosphamide after mastectomy for breast cancer.

4. Randomised comparative studies in the treatment of cancer in the United Kingdom: room for improvement?

5. Antiestrogen treatment of postmenopausal women with primary high risk breast cancer.

6. Adjuvant tamoxifen for operable carcinoma of the breast: report of clinical trial by the Christie Hospital and Holt Radium Institute.

Review 1. Long-term adjuvant tamoxifen therapy for breast cancer.

Review 2. Systemic adjuvant therapy for node-negative breast cancer.

Review 3. Adjuvant systemic therapy: state of the art, 1989.

Review 4. Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program.

Review 5. NSABP breast cancer clinical trials: recent results and future directions.

Review 6. Tamoxifen and secondary tumours. An update.

Review 7. Gynecologic effects of tamoxifen: case reports and review of the literature.

Review 8. Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Review 9. Prevention of breast cancer recurrence with adjuvant cytotoxic or endocrine therapy.

10. Survival effect of systemic therapy on patients developing metastatic breast carcinoma.